<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04637048</url>
  </required_header>
  <id_info>
    <org_study_id>Obs-Hepatobiliary CA</org_study_id>
    <nct_id>NCT04637048</nct_id>
  </id_info>
  <brief_title>Observational Study on Patients With Hepatobiliary Tumors</brief_title>
  <official_title>Observational Study on Patients With Hepatobiliary Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gang Chen, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital of Wenzhou Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatobiliary tumors have a poor prognosis and high individual heterogeneity, the patient&#xD;
      with hepatobiliary tumors even accepted radical surgery, the postoperative recurrence rate is&#xD;
      still high. Therefore, it is of great significance to find important prognostic markers to&#xD;
      improve patient prognosis and formulate new treatment plans after surgery. In recent years,&#xD;
      targeted therapy and immunotherapy make cancer treatment enter a new field, However, tumor&#xD;
      heterogeneity is the greatest challenge in cancer therapeutics and biomarkers discovery. In&#xD;
      this study, we obtained blood and pathological tissue specimens from tumor patients, then&#xD;
      Multi-omics testing were applied to Looking for novel therapeutic targets and prognostic&#xD;
      markers to predict patient response to treatment. Clinicians choose the best treatment plan&#xD;
      for the patient based on the test results to improve the patient's survival time and quality&#xD;
      of life.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an ongoing, longitudinal, single centre, observational clinical cohort study of&#xD;
      patients with hepatobiliary tumors. All the patients are diagnosed, treated and followed up&#xD;
      by The First Affiliate hospital of Wenzhou medical university.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 16, 2017</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the overall survival rate of all patients with hepatobiliary tumor</measure>
    <time_frame>5 years</time_frame>
    <description>In order to identify the potential influence factors of hepatobiliary tumor patients survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the recurrence free survival rate of patients with hepatobiliary tumor</measure>
    <time_frame>5 years</time_frame>
    <description>In order to identify the potential influence factors of tumor recurrencesamples from patients with hepatobiliary cancers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the cancer-specific survival rate of patients with hepatobiliary tumor</measure>
    <time_frame>5 years</time_frame>
    <description>In order to identify the potential influence factors of tumor-induced death in patients with hepatobiliary tumors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the Progression Free Survival rate of patients with hepatobiliary tumor</measure>
    <time_frame>5 years</time_frame>
    <description>In order to identify the potential influence factors of tumor progression from patients with hepatobiliary cancers</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Cholangiocarcinoma</condition>
  <condition>Gallbladder Cancer</condition>
  <condition>Biliary Tract Cancer</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      normal tissue, tumor samples, blood, urine, feces, ascites, bile samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed and treated as hepatobiliary tumors in the first affiliate hospital of&#xD;
        wenzhou medical university&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Be older than 18 years old;&#xD;
&#xD;
          2. Clinical or pathological diagnosis of malignant hepatobiliary tumors;&#xD;
&#xD;
          3. Patients have received or are about to receive surgery, chemotherapy radiotherapy,&#xD;
             targeted therapy, local therapy, immunotherapy, etc;&#xD;
&#xD;
          4. Patients understand and are willing to sign written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients considered by the doctor to be unsuitable for entry into this study (mental&#xD;
             disorder or poor compliance, etc.);&#xD;
&#xD;
          2. The patient or guardian is unwilling to participate in this study;&#xD;
&#xD;
          3. Pregnant women;&#xD;
&#xD;
          4. Combined with other serious systemic diseases (heart failure, renal&#xD;
             failure,hematopoietic system disease or Uncontrollable acute infection);&#xD;
&#xD;
          5. Estimated survival time is less than 1 month.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gang Chen, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital of Wenzhou Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gang Chen, M.D.</last_name>
    <phone>+86-13616619566</phone>
    <email>chen.gang@wmu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gang Chen</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <zip>325000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gang Chen, M.D.</last_name>
      <phone>+86-13616619566</phone>
      <email>chen.gang@wmu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Gang Chen, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yi Wang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lijun Wu, M.M.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Liming Deng, M.M.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Haitao Yu, M.M.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jinhuan Yang, M.M.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jungang Zhao, M.M.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 14, 2020</study_first_submitted>
  <study_first_submitted_qc>November 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2020</study_first_posted>
  <last_update_submitted>November 25, 2020</last_update_submitted>
  <last_update_submitted_qc>November 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>First Affiliated Hospital of Wenzhou Medical University</investigator_affiliation>
    <investigator_full_name>Gang Chen, MD</investigator_full_name>
    <investigator_title>Division Chief of Education; Deputy Director of Hepatobiliary Surgery</investigator_title>
  </responsible_party>
  <keyword>Hepatocellular Carcinoma</keyword>
  <keyword>Cholangiocarcinoma</keyword>
  <keyword>Gallbladder Cancer</keyword>
  <keyword>Biliary Tract Cancer</keyword>
  <keyword>blood sample</keyword>
  <keyword>tissue sample</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
    <mesh_term>Biliary Tract Neoplasms</mesh_term>
    <mesh_term>Gallbladder Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

